Home/Stocks/Financials

Man Group PLC

EMG.L·Financials·Market Cap £3.9b
Rank #32 of 280
Quantitative Model · 280 Stocks Analysed
£3.39
+48.25% YTD
52W: £1.83 - £3.49

Factor Analysis Summary

Editorial assessment generated from Man Group PLC's live factor scores and sector positioning.

Based on Strategyland's proprietary 7-factor analysis, Man Group PLC (EMG.L) currently holds an overall rank of #32 out of 280 FTSE 100 constituents, reflecting its weighted composite score across liquidity, valuation, profitability, solvency, asset efficiency, market trading, and technical dimensions.

Key strengths include liquidity, where it demonstrates exceptional market liquidity with deep trading volumes that support efficient entry and exit; technical (RSI 47.6), where it demonstrates generally favourable technical indicators with price holding above key moving averages; and profitability (ROE 10.8%, net margin 18.7%), where it demonstrates healthy profit margins and returns that exceed the median FTSE 100 company.

Areas requiring attention include solvency (debt/equity 0.2), where balance sheet metrics are unexceptional and offer limited downside protection, as well as valuation (P/E 16.0, dividend yield 4.4%), where valuation offers limited margin of safety at current price levels.

Within the Financials sector, Man Group PLC sits at composite rank #32, trailing the Financials peer average (rank 8). It ranks behind all 6 tracked Financials peers in our model.

Ranking in the top quartile overall, Man Group PLC offers a favourable balance of fundamentals, though investors should weigh its liquidity advantage against solvency — its relatively weakest factor.

Strongest Factors

  • Liquidity — Rank 4/280 (top quartile)
  • Technical — Rank 72/280 (above average)
  • Profitability — Rank 78/280 (above average)

Weakest Factors

  • Solvency — Rank 164/280 (middle of the pack)
  • Valuation — Rank 155/280 (middle of the pack)

Score Analysis

Man Group PLC is ranked #32 out of 280 UK stocks. Lower factor scores indicate better performance in that category.

Factor Breakdown

110/280
Average Score
Liquidity
Excellent4/280
Valuation
Fair155/280
Profitability
Good78/280
Solvency
Fair164/280
Asset Efficiency
Fair153/280
Mkt Trading
Fair145/280
Technical
Good72/280

1. Liquidity

Score: 4/280

How liquid is EMG and can it meet its short-term obligations?

0/6
liquidity criteria met
–
Quick RatioN/A
Range: N/A
–
Current RatioN/A
Range: N/A
–
TTM Operating Cash FlowN/A
Range: N/A
–
Liquidity Coverage RatioN/A
Range: 100-150
✗
Intangible Asset Ratio0.04x
Range: 10 - 30Rank 84/280
–
Cash-to-Debt Ratio0.61x
Range: N/ARank 78/280

Key Liquidity Metrics

Quick Ratio
N/A
Sector: N/A
Current Ratio
N/A
Sector: N/A

Overall Liquidity Rank

Rank within universe#4/280
Best (1)Worst (280)

2. Valuation

Score: 155/280

Is EMG undervalued compared to its peers and fair value metrics?

3/7
valuation criteria met
✓
FY27e P/E9.4x
Range: 8x - 18xRank 47/280
✓
FY26e P/E9.6x
Range: 8x - 18xRank 39/280
✓
FY27e Net Div Yld (%)6.22%
Range: 3.0 - 8.0Rank 44/280
✗
Div Payout Ratio59.96%
Range: 30 - 55Rank 100/280
–
Current EV/EBITDA9.2x
Range: N/ARank 159/280
✗
Current P/TBV4.91x
Range: 0.8x - 2.0xRank 173/280
✗
Current P/B2.25x
Range: 0.8x - 2.0xRank 181/280

Key Valuation Metrics

TTM P/E
Price-to-Earnings
16.0x
FY26e P/E
Forward estimate
9.6x
FY27e P/E
Forward estimate
9.4x
Current P/B
Price-to-Book
2.25x
Current P/TBV
Tangible Book Value
4.91x
Current EV/EBITDA
Enterprise Value
9.2x
FY26e EV/EBITDA
Forward estimate
6.6x
FY27e EV/EBITDA
Forward estimate
6.6x

Dividend

EMG pays a dividend yield of 4.42%.

Current Yield
4.42%
FY27e Net Div Yield
6.22%
FY26e Gross DPS
0.194
FY27e Gross DPS
0.211

Dividend Per Share Forecast

3. Profitability

Score: 78/280

How profitable is EMG relative to its peers?

1/7
profitability criteria met
✓
TTM Profit Margin18.7%
Range: 15 - 30Rank 115/280
–
T12 FCF Margin0.4%
Range: N/ARank 109/280
✗
FY27e RoE25.7%
Range: 10 - 16Rank 53/280
✗
FY26 EPS Growth69.5%
Range: 8 - 15Rank 22/280
✗
FY27e EPS Growth73.5%
Range: 6 - 12Rank 27/280
–
NIMN/A
Range: 1.5 - 3.2
–
Expense RatioN/A
Range: 50 - 65
TTM Profit Margin
18.7%
Current RoCE
10.8%
FY27e RoE
25.7%
T12 FCF Margin
0.4%

EPS Growth

4. Solvency

Score: 164/280

How strong is EMG's balance sheet and financial position?

0/6
solvency criteria met
✗
Debt/Eqt0.18x
Range: 0.5x - 1.5xRank 89/280
–
Interest Coverage RatioRank 97
Range: N/ARank 97/280
–
Net Leverage RatioN/A
Range: N/A
–
Altman Z-Score (Manufacturing)N/A
Range: N/ARank 240/280
–
Z-Score (Non Manufacturing)Rank 246
Range: N/ARank 246/280
–
CapAdeq Ratio Tier1N/A
Range: 13 - 18

Key Solvency Metrics

Debt/Eqt
0.18x
Net Leverage Ratio
N/A
Interest Coverage
Rank 97
T12 FCF Margin
0.4%

Altman Z-Score

N/A
Distress Zone
01.812.995+

5. Asset Efficiency

Score: 153/280

How efficiently does EMG deploy its assets and intellectual capital?

1/5
asset efficiency criteria met
–
Efficiency RatioN/A
Range: 50 - 70
–
TTM Asset Turnover Ratio0.40x
Range: N/ARank 145/280
✓
TTM CAPEX/Sales2.4%
Range: 1 - 3Rank 145/280
–
Working Capital TurnoverN/A
Range: N/A
–
R&D/Sales FY27eN/A
Range: N/A

Overall Asset Efficiency Rank

Rank within sector peers#153/280
Best (1)Worst (280)

6. Market Trading

Score: 145/280

How liquid and actively traded is EMG?

1/2
market trading criteria met
✗
Intraday Sentiment (%)100.0%
Range: 40 - 75Rank 1/280
–
10D-Avg v/s 3M-Avg Vol91%
Range: N/ARank 50/280
✓
Avg Directional Index 30D17.2
Range: 012 - 45Rank 175/280
–
Parabolic SAR315.46
Range: N/ARank 199/280
–
Stock Rating RankRank 50
Range: N/ARank 50/280
Market Cap
£3,870,473,075
Enterprise Value
£5,276,738,405

Trading Volume

7. Technical

Score: 72/280

What do the technical indicators say about EMG?

0/5
technical criteria met
–
CMP v/s 52-WH-2.8%
£3.49£1.83
-2.8%CMP: £3.39
Range: N/ARank 27/280
–
CMP v/s 52-WL85.1%
£3.49£1.83
+85.1%CMP: £3.39
Range: N/ARank 263/280
–
RSI 14D47.6
047.6 - Bearish100
Range: N/ARank 50/280
–
MA50 - MA200Bullish
£2.83+0.33£3.16
Range: N/ARank 96/280
–
MACD Rank-0.02
Golden Cross
MACD: -0.02
Range: N/A

RSI (14 Day)

47.6
Bearish
0 (Oversold)50100 (Overbought)

Moving Averages

50 SMA£3.16
200 SMA£2.83
SignalGolden Cross (Bullish)
MACD-0.02

Risk Metrics

Beta
N/A
3-Yr Std Dev
0.3%
5-Yr Std Dev
0.3%

Peer Comparison

How does EMG compare to other Financials stocks?

Overall Rank Comparison

Factor Score Comparison

StockRankLiquidityValuationProfitabilitySolvencyMkt TradingTechnical
EMG#3241557816414572
MUT.L#3128382456278
RTW.L#51167914569229
BPCR.L#71633456911276
RCP.L#9179262259132
AGT.L#111085755729079
TBCG.L#1429553825712918
Sponsored
Healthcare Discovery Monitor
Live
Healthcare Discovery Monitor
Healthcare Discovery Monitorby StrategyLand

Catch Healthcare Events Before the Market Moves

SEC filings, FDA approvals, clinical trials, and regulatory events - scored for significance across 4 global markets.

10+
Sources
4
Markets
12h
Cycle
50+
Keywords
USUKCNEU
Launch Monitor

Methodology Note

The analysis presented for Man Group PLC is produced using Strategyland's proprietary 7-factor quantitative model, which evaluates each stock across Liquidity, Valuation, Profitability, Solvency, Asset Efficiency, Market Trading, and Technical dimensions. Individual factor scores and the composite rank reflect relative rankings within the FTSE 100 universe — a lower rank number indicates stronger performance in that category.

Underlying financial and market data is sourced from LSEG (London Stock Exchange Group) and processed through our scoring engine. Scores are recalculated as new data becomes available and should be interpreted as a systematic screening output, not a forecast of future share price performance.

This content is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance and factor rankings are not indicative of future results. Please read our Risk Disclaimer before making any investment decisions.

Note: The information provided is not intended as an offer or solicitation for the purchase or sale of any financial instruments but for investor relations purposes only. The aforementioned securities were offered to the public and currently trade on the secondary market at the exchange mentioned above. It is recommended that investors considering investing in any of these notes consult an approved MiFID Financial Advisor prior to investing.